Evaxion A/S announced on July 1, 2025, several key changes to its Executive Management aimed at optimizing value from its proprietary AI-Immunology platform and pipeline. Christian Kanstrup stepped down as Chief Executive Officer (CEO).
Dr. Birgitte Rønø, Evaxion’s Chief Scientific Officer, has been appointed interim CEO, providing leadership continuity given her tenure since 2017 and her role in Executive Management since 2021. Thomas Schmidt, who joined as interim CFO in November 2024, has been appointed permanent Chief Financial Officer.
The Board of Directors has initiated a search for a new permanent CEO with a strong business development focus, proven transformational leadership, and the executional capabilities required to drive strategic partnerships for the company.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.